Tratamiento farmacológico y nutricional para la enfermedad de McArdle (enfermedad por almacenamiento de glucógeno tipo V)
Información
- DOI:
- https://doi.org/10.1002/14651858.CD003458.pub5Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 12 noviembre 2014see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Neuromuscular
- Copyright:
-
- Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
RQ and RB were involved in the original review and agreed criteria for inclusion of studies and their methodological quality. RQ and MA were involved in assessing the two new studies included in the 2010 update. RQ completed the first and second updated drafts in 2010 with agreement and approval from RB and MA. RQ completed this 2014 update with agreement and approval of AM and BS.
Sources of support
Internal sources
-
None, Other.
External sources
-
None, Other.
Declarations of interest
RQ was involved in the conduct of a randomised cross‐over placebo‐controlled trial of vitamin B6, which did not demonstrate any overall benefit. RQ received an honorarium from Genzyme in July 2010 for lecturing on metabolic muscle disease. She has a grant from the muscular dystrophy campaign and European Union for McArdle disease research.
AM was involved in the conduct of a RCT of ramipril which did not demonstrate any significant benefit. In relation to this trial his institution received a project grant from Telethon, Italy. His institution also received an European Union grant for the EUROMAC project, establishing a European registry for muscle glycogenoses.
BS was involved in an unblinded observational study of high fat diet which showed no benefit. BS has received payment for membership of the Genzyme Pompe disease advisory board and for advice on Pompe disease to Biomarin Ltd. He has received payment for lectures from Genzyme, Biomarin and CSL Behring.
Acknowledgements
Rob Beynon (RB) was second author in the original review and first two updates.
We thank the Muscular Dystrophy Campaign of Great Britain and the Association for Glycogen Storage Diseases (AGSD). We dedicate this review to Nicholas Owston, who sadly died in 2003, in acknowledgement of his untiring support through the AGSD.
Editorial support from the Cochrane Neuromuscular Disease Group for earlier updates was funded by the TREAT NMD Network European Union Grant 036825. For the 2013 update, the editorial base of the Cochrane Neuromuscular Disease Group was supported by the MRC Centre for Neuromuscular Diseases and the Muscular Dystrophy Campaign.
Version history
| Published | Title | Stage | Authors | Version |
| 2014 Nov 12 | Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V) | Review | Rosaline Quinlivan, Andrea Martinuzzi, Benedikt Schoser | |
| 2010 Dec 08 | Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V) | Review | Rosaline Quinlivan, Andrea Martinuzzi, Benedikt Schoser | |
| 2008 Apr 23 | Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V) | Review | Rosaline Quinlivan, Robert J Beynon, Andrea Martinuzzi | |
| 2004 Jul 19 | Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V) | Review | Rosaline Quinlivan, Robert J Beynon | |
| 2002 Jan 21 | Pharmacological and nutritional treatment for McArdle's disease (Glycogen storage disease type V) | Protocol | Ros Quinlivan, Robert J Beynon | |
Differences between protocol and review
In the 2010 update of the review, the review authors assessed risk of bias according to the Cochrane 'Risk of bias' assessment method (Higgins 2008). The terminology for the 'Risk of bias' assessments changed at this update (Higgins 2011).
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
- *Dietary Supplements;
- Creatine [administration & dosage];
- Dietary Carbohydrates [administration & dosage];
- Dietary Proteins;
- Glycogen Storage Disease Type V [drug therapy, *therapy];
- Physical Endurance;
- Ramipril [therapeutic use];
- Randomized Controlled Trials as Topic;
- Sucrose [administration & dosage];
Medical Subject Headings Check Words
Humans;
PICO
Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (‐) = high risk of bias; yellow (?) = unclear risk of bias, green (+) = low risk of bias.
